Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients

被引:45
|
作者
Sanchez-Conde, M. [1 ]
Miralles, P. [1 ]
Maria Bellon, J. [2 ]
Rincon, D. [3 ]
Ramirez, M. [1 ]
Gutierrez, I. [1 ]
Ripoll, C. [3 ]
Lopez, J. C. [1 ]
Cosin, J. [1 ]
Clemente, G. [3 ]
Lo Iacono, O. [3 ]
Banares, R. [3 ,4 ]
Berenguer, J. [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Infect Dis & HIV Unit, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Biomed Res Fdn, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Hepatol Unit, Madrid, Spain
[4] Spanish CIBERehd Res Grp, Barcelona, Spain
关键词
hepatitis C infection; HIV infection; liver cirrhosis; liver pathology; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; VENOUS-PRESSURE GRADIENT; STAGE LIVER-DISEASE; INFECTED PATIENTS; THERAPEUTIC STRATEGIES; NATURAL-HISTORY; FIBROSIS; CIRRHOSIS; PROGRESSION;
D O I
10.1111/j.1365-2893.2010.01371.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure and correlates with the occurrence of portal hypertension (PH)-related complications. Transient elastography (TE) is a new, highly accurate noninvasive technique, which enables us to evaluate hepatic fibrosis to detect advanced fibrosis and cirrhosis. We performed a hepatic haemodynamic study and TE in 38 HIV/HCV-coinfected patients. The association between HVPG and liver stiffness was assessed by linear regression. The diagnostic value of TE was assessed by receiver operating characteristic (ROC) curves. We considered clinically significant PH as an HVPG >= 10 mmHg and severe PH as an HVPG 12 mmHg. A total of 38 HIV/HCV-coinfected patients were included. Twenty-eight patients (73.7%) had clinically significant PH (HVPG >= 10 mmHg), and 23 (60.5%) of these had severe PH (HVPG >= 12 mmHg). We found a statistically significant association between liver stiffness (kPa) and HVPG(r(2) = 0.46, P < 0.001, straight line equation HVPG = 7.4 + 0.204*TE). The areas under the ROC curves were 0.80 [95% confidence interval (CI), 0.64-0.97] and 0.80 (95% CI, 0.66-0.94) for the prediction of HVPG 10 and 12 mmHg, respectively. Our data suggest that TE can predict the presence of clinically significant and severe PH in HIV/HCV-coinfected patients.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 50 条
  • [21] Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan®)
    Lupsor-Platon, Monica
    Badea, Radu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (42) : 11914 - 11923
  • [22] Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography(Fibroscan~)
    Monica Lupsor-Platon
    Radu Badea
    World Journal of Gastroenterology, 2015, (42) : 11914 - 11923
  • [23] Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
    Perez-Latorre, Leire
    Sanchez-Conde, Matilde
    Miralles, Pilar
    Carlos Lopez, Juan
    Parras, Francisco
    Tejerina, Francisco
    Aldamiz-Echevarria, Teresa
    Carrero, Ana
    Diez, Cristina
    Ramirez, Margarita
    Gutierrez, Isabel
    Maria Bellon, Jose
    Banares, Rafael
    Berenguer, Juan
    BMC INFECTIOUS DISEASES, 2018, 18
  • [24] Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients
    Laguno, M
    Milinkovic, A
    de Lazzari, E
    Murillas, J
    Martínez, E
    Blanco, JL
    Loncá, M
    Biglia, A
    Leon, A
    García, M
    Larrousse, M
    García, F
    Miró, JM
    Gatell, JM
    Mallolas, J
    ANTIVIRAL THERAPY, 2005, 10 (03) : 423 - 429
  • [25] INTERFERON-FREE DAA REGIMENS DECREASE PORTAL PRESSURE AND HALT HISTOLOGICAL NECROINFLAMMATION IN HIV/HCV-COINFECTED PATIENTS
    Schwabl, P.
    Mandorfer, M.
    Steiner, S.
    Scheiner, B.
    Bucsics, T.
    Aichelburg, M.
    Grabmeier-Pfistershammer, K.
    Sieghart, W.
    Ferlitsch, A.
    Trauner, M.
    Reiberger, T.
    Peck-Radosavljevic, M.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S623 - S623
  • [26] Genetic Polymorphisms Associated with Liver Disease Progression in HIV/HCV-Coinfected Patients
    Medrano, Luz M.
    Jimenez-Sousa, Maria A.
    Fernandez-Rodriguez, Amanda
    Resino, Salvador
    AIDS REVIEWS, 2017, 19 (01) : 3 - 15
  • [27] Understanding the Mechanisms of Fibrogenesis in HIV/HCV-Coinfected Patients: Implications for Clinical Practice
    Sacchi, Paolo
    Cima, Serena
    Zuccaro, Valentina
    Columpsi, Paola
    Sarda, Cristina
    Mariani, Marcello
    Puoti, Massimo
    Bruno, Raffaele
    AIDS REVIEWS, 2015, 17 (03) : 159 - 170
  • [28] Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
    Leire Pérez-Latorre
    Matilde Sánchez-Conde
    Pilar Miralles
    Juan Carlos López
    Francisco Parras
    Francisco Tejerina
    Teresa Aldámiz-Echevarría
    Ana Carrero
    Cristina Díez
    Margarita Ramírez
    Isabel Gutiérrez
    José María Bellón
    Rafael Bañares
    Juan Berenguer
    BMC Infectious Diseases, 18
  • [29] Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype
    Caudai, C
    Pianese, M
    Zacchini, F
    Toti, M
    Zazzi, M
    Valensin, PE
    JOURNAL OF CLINICAL VIROLOGY, 2005, 32 (02) : 151 - 155
  • [30] Metabolic syndrome and progression of liver fibrosis in HIV/HCV-coinfected patients on HAART
    Barreiro, P.
    Blanco, F.
    de Mendoza, C.
    Zahonero, N.
    Martin-Carbonero, L.
    Melian, E.
    Fernandez-Vazquez, G.
    Sanchez-Franco, F.
    Gonzalez-Lahoz, J.
    Soriano, V.
    ANTIVIRAL THERAPY, 2007, 12 (06) : L64 - L65